piggyBac-mediated phenotypic correction of factor VIII deficiency

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 14042-

  Staber, Janice M ^a   Pollpeter, Molly J ^a   Arensdorf, Angela ^a   Sinn, Patrick L ^a   Rutkowski, D Thomas ^a   McCray, Paul B ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; COMPLEMENTARY DNA; RINGER LACTATE SOLUTION; TRANSPOSASE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRESS; CODON; CONTROLLED STUDY; DNA VECTOR; ENDOPLASMIC RETICULUM STRESS; FEMALE; GENE EXPRESSION; GENETIC ENGINEERING; HEMOPHILIA A; HYDRODYNAMICS; IMMUNOCOMPETENT CELL; LIVER CELL; MALE; MAMMAL CELL; MOUSE; MOUSE MODEL; NONHUMAN; PIGGYBAC VECTOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TARGETED GENE REPAIR; TRANSGENE; TRANSPOSON;

EID: 85015211115     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2014.42     Document Type: Article

References (48)

1. 1 Graw, J, Brackmann, HH, Oldenburg, J, Schneppenheim, R, Spannagl, M, Schwaab, R, Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet 6 (2005), 488–501.
2. 2 Bolton-Maggs, PH, Pasi, KJ, Haemophilias A and B. Lancet 361 (2003), 1801–1809.
3. 3 High, KA, Gene transfer as an approach to treating hemophilia. Circ Res 88 (2001), 137–144.
4. 4 Yant, SR, Meuse, L, Chiu, W, Ivics, Z, Izsvak, Z, Kay, MA, Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 25 (2000), 35–41.
5. 5 Chavez, CL, Keravala, A, Chu, JN, Farruggio, AP, Cuéllar, VE, Voorberg, J, et al. Long-term expression of human coagulation factor VIII in a tolerant mouse model using the fC31 integrase system. Hum Gene Ther 23 (2012), 390–398.
6. 6 Kuether, EL, Schroeder, JA, Fahs, SA, Cooley, BC, Chen, Y, Montgomery, RR, et al. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity. J Thromb Haemost 10 (2012), 1570–1580.
7. 7 Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365 (2011), 2357–2365.
8. 8 Finn, JD, Ozelo, MC, Sabatino, DE, Franck, HW, Merricks, EP, Crudele, JM, et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood 116 (2010), 5842–5848.
9. 9 Groth, AC, Calos, MP, Phage integrases: biology and applications. J Mol Biol 335 (2004), 667–678.
10. 10 Cary, LC, Goebel, M, Corsaro, BG, Wang, HG, Rosen, E, Fraser, MJ, Transposon mutagenesis of baculoviruses: analysis of Trichoplusia ni transposon IFP2 insertions within the FP-locus of nuclear polyhedrosis viruses. Virology 172 (1989), 156–169.
11. 11 Burnight, ER, Staber, JM, Korsakov, P, Li, X, Brett, BT, Scheetz, TE, et al. A Hyperactive Transposase Promotes Persistent Gene Transfer of a piggyBac DNA Transposon. Mol Ther Nucleic Acids, 1, 2012, e50.
12. 12 Li, MA, Turner, DJ, Ning, Z, Yusa, K, Liang, Q, Eckert, S, et al. Mobilization of giant piggyBac transposons in the mouse genome. Nucleic Acids Res, 39, 2011, e148.
13. 13 Ding, S, Wu, X, Li, G, Han, M, Zhuang, Y, Xu, T, Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 122 (2005), 473–483.
14. 14 Toole, JJ, Pittman, DD, Orr, EC, Murtha, P, Wasley, LC, Kaufman, RJ, A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 83 (1986), 5939–5942.
15. 15 Ward, NJ, Buckley, SM, Waddington, SN, Vandendriessche, T, Chuah, MK, Nathwani, AC, et al. Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood 117 (2011), 798–807.
16. 16 Kang, Y, Xie, L, Tran, DT, Stein, CS, Hickey, M, Davidson, BL, et al. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Blood 106 (2005), 1552–1558.
17. 17 Bi, L, Lawler, AM, Antonarakis, SE, High, KA, Gearhart, JD, Kazazian, HH Jr, Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 10 (1995), 119–121.
18. 18 Suda, T, Gao, X, Stolz, DB, Liu, D, Structural impact of hydrodynamic injection on mouse liver. Gene Ther 14 (2007), 129–137.
19. 19 Malhotra, JD, Miao, H, Zhang, K, Wolfson, A, Pennathur, S, Pipe, SW, et al. Antioxidants reduce endoplasmic reticulum stress and improve protein secretion. Proc Natl Acad Sci USA 105 (2008), 18525–18530.
20. 20 Rutkowski, DT, Arnold, SM, Miller, CN, Wu, J, Li, J, Gunnison, KM, et al. Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biol, 4, 2006, e374.
21. 21 Chikka, MR, McCabe, DD, Tyra, HM, Rutkowski, DT, C/EBP homologous protein (CHOP) contributes to suppression of metabolic genes during endoplasmic reticulum stress in the liver. J Biol Chem 288 (2013), 4405–4415.
22. 22 Liu, CL, Ye, P, Yen, BC, Miao, CH, In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy. Mol Ther 19 (2011), 1511–1520.
23. 23 Sack, BK, Merchant, S, Markusic, DM, Nathwani, AC, Davidoff, AM, Byrne, BJ, et al. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. PLoS ONE, 7, 2012, e37671.
24. 24 Matsui, H, Hegadorn, C, Ozelo, M, Burnett, E, Tuttle, A, Labelle, A, et al. A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A. Mol Ther 19 (2011), 723–730.
25. 25 Ramezani, A, Hawley, RG, Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector. Blood 114 (2009), 526–534.
26. 26 VandenDriessche, T, Vanslembrouck, V, Goovaerts, I, Zwinnen, H, Vanderhaeghen, ML, Collen, D, et al. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc Natl Acad Sci USA 96 (1999), 10379–10384.
27. 27 Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118 (2008), 3132–3142.
28. 28 Johnston, JM, Denning, G, Doering, CB, Spencer, HT, Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A. Gene Ther 20 (2013), 607–615.
29. 29 Ohlfest, JR, Frandsen, JL, Fritz, S, Lobitz, PD, Perkinson, SG, Clark, KJ, et al. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood 105 (2005), 2691–2698.
30. 30 Pipe, SW, Morris, JA, Shah, J, Kaufman, RJ, Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem 273 (1998), 8537–8544.
31. 31 Khrenov, AV, Ananyeva, NM, Saenko, EL, Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X. Blood Coagul Fibrinolysis 17 (2006), 379–388.
32. 32 Miao, HZ, Sirachainan, N, Palmer, L, Kucab, P, Cunningham, MA, Kaufman, RJ, et al. Bioengineering of coagulation factor VIII for improved secretion. Blood 103 (2004), 3412–3419.
33. 33 Liu, F, Song, Y, Liu, D, Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6 (1999), 1258–1266.
34. 34 Hackett, PB Jr, Aronovich, EL, Hunter, D, Urness, M, Bell, JB, Kass, SJ, et al. Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies. Curr Gene Ther 11 (2011), 341–349.
35. 35 Qiao, C, Li, J, Zheng, H, Bogan, J, Li, J, Yuan, Z, et al. Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum Gene Ther 20 (2009), 1–10.
36. 36 Noble, ML, Kuhr, CS, Graves, SS, Loeb, KR, Sun, SS, Keilman, GW, et al. Ultrasound-targeted microbubble destruction-mediated gene delivery into canine livers. Mol Ther 21 (2013), 1687–1694.
37. 37 Manuri, PV, Wilson, MH, Maiti, SN, Mi, T, Singh, H, Olivares, S, et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther 21 (2010), 427–437.
38. 38 Bayer, M, Kantor, B, Cockrell, A, Ma, H, Zeithaml, B, Li, X, et al. A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector. Mol Ther 16 (2008), 1968–1976.
39. 39 Vink, CA, Gaspar, HB, Gabriel, R, Schmidt, M, McIvor, RS, Thrasher, AJ, et al. Sleeping beauty transposition from nonintegrating lentivirus. Mol Ther 17 (2009), 1197–1204.
40. 40 Hausl, MA, Zhang, W, Müther, N, Rauschhuber, C, Franck, HG, Merricks, EP, et al. Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B. Mol Ther 18 (2010), 1896–1906.
41. 41 Zhang, W, Muck-Hausl, M, Wang, J, Sun, C, Gebbing, M, Miskey, C, et al. Integration profile and safety of an adenovirus hybrid-vector utilizing hyperactive sleeping beauty transposase for somatic integration. PLoS ONE, 8, 2013, e75344.
42. 42 Wu, SC, Meir, YJ, Coates, CJ, Handler, AM, Pelczar, P, Moisyadi, S, et al. piggyBac is a flexible and highly active transposon as compared to sleeping beauty, Tol2, and Mos1 in mammalian cells. Proc Natl Acad Sci USA 103 (2006), 15008–15013.
43. 43 Li, X, Lobo, N, Bauser, CA, Fraser, MJ Jr, The minimum internal and external sequence requirements for transposition of the eukaryotic transformation vector piggyBac. Mol Genet Genomics 266 (2001), 190–198.
44. 44 Bell, JB, Podetz-Pedersen, KM, Aronovich, EL, Belur, LR, McIvor, RS, Hackett, PB, Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection. Nat Protoc 2 (2007), 3153–3165.
45. 45 Kasper, CK, Aledort, L, Aronson, D, Counts, R, Edson, JR, van Eys, J, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh, 34, 1975, 612.
46. 46 Meeks, SL, Healey, JF, Parker, ET, Barrow, RT, Lollar, P, Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model. J Thromb Haemost 7 (2009), 658–664.
47. 47 Keith, JH, Schaeper, CA, Fraser, TS, Fraser, MJ Jr, Mutational analysis of highly conserved aspartate residues essential to the catalytic core of the piggyBac transposase. BMC Mol Biol, 9, 2008, 73.
48. 48 Sarkar, A, Sim, C, Hong, YS, Hogan, JR, Fraser, MJ, Robertson, HM, et al. Molecular evolutionary analysis of the widespread piggyBac transposon family and related “domesticated” sequences. Mol Genet Genomics 270 (2003), 173–180.